DK1930007T3 - Anvendelse af renolazin til fremstilling af et medikament til behandling af tidlige efterdepolarisationer (EADs) - Google Patents

Anvendelse af renolazin til fremstilling af et medikament til behandling af tidlige efterdepolarisationer (EADs)

Info

Publication number: DK1930007T3
Authority: DK; Denmark
Prior art keywords: renolazine; postpolarizations; eads; medication; early
Prior art date: 2002-04-04

Application number

DK08004276.5T

Other languages

English (en)

Inventor

Luiz Belardinelli

Charles Antzelevitch

Brent Blackburn

Original Assignee

Gilead Palo Alto Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-04-04

Filing date

2003-04-04

Publication date

2010-08-30

2003-04-04 Application filed by Gilead Palo Alto Inc filed Critical Gilead Palo Alto Inc

2010-08-30 Application granted granted Critical

2010-08-30 Publication of DK1930007T3 publication Critical patent/DK1930007T3/da

Links

229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
RJNSNFZXAZXOFX-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide;hydron;dichloride Chemical compound Cl.Cl.COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 RJNSNFZXAZXOFX-UHFFFAOYSA-N 0.000 title 1
208000018452 Torsade de pointes Diseases 0.000 abstract 2
208000002363 Torsades de Pointes Diseases 0.000 abstract 2
208000001871 Tachycardia Diseases 0.000 abstract 1
206010003119 arrhythmia Diseases 0.000 abstract 1
230000006793 arrhythmia Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
208000031352 familial ventricular tachycardia Diseases 0.000 abstract 1
208000012404 paroxysmal familial ventricular fibrillation Diseases 0.000 abstract 1
230000006794 tachycardia Effects 0.000 abstract 1
206010047302 ventricular tachycardia Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

DK08004276.5T 2002-04-04 2003-04-04 Anvendelse af renolazin til fremstilling af et medikament til behandling af tidlige efterdepolarisationer (EADs) DK1930007T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US37015002P	2002-04-04	2002-04-04
US40829202P	2002-09-05	2002-09-05
US42258902P	2002-10-30	2002-10-30
EP03723907A EP1490066B1 (en)	2002-04-04	2003-04-04	Use of ranolazine for the preparation of a medicament for the treatment of arrhythmias

Publications (1)

Publication Number	Publication Date
DK1930007T3 true DK1930007T3 (da)	2010-08-30

Family

ID=29255318

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08004276.5T DK1930007T3 (da)	2002-04-04	2003-04-04	Anvendelse af renolazin til fremstilling af et medikament til behandling af tidlige efterdepolarisationer (EADs)
DK03723907T DK1490066T3 (da)	2002-04-04	2003-04-04	Anvendelse af ranolazin til fremstilling af et medikament til behandling af arytmier

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK03723907T DK1490066T3 (da)	2002-04-04	2003-04-04	Anvendelse af ranolazin til fremstilling af et medikament til behandling af arytmier

Country Status (19)

Country	Link
US (2)	US20030220344A1 (da)
EP (3)	EP1490066B1 (da)
JP (1)	JP4608217B2 (da)
KR (2)	KR20040099395A (da)
CN (2)	CN101843619A (da)
AT (2)	ATE397932T1 (da)
AU (3)	AU2003230810B2 (da)
CA (1)	CA2481192C (da)
CY (1)	CY1110400T1 (da)
DE (2)	DE60332975D1 (da)
DK (2)	DK1930007T3 (da)
ES (2)	ES2304507T3 (da)
IL (1)	IL197406A0 (da)
MX (1)	MXPA04009637A (da)
NO (1)	NO330953B1 (da)
NZ (1)	NZ535610A (da)
PT (2)	PT1490066E (da)
SI (2)	SI1930007T1 (da)
WO (1)	WO2003086401A1 (da)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030220344A1 (en) *	2002-04-04	2003-11-27	Luiz Belardinelli	Method of treating arrhythmias
US8822473B2 (en) *	2002-05-21	2014-09-02	Gilead Sciences, Inc.	Method of treating diabetes
CN100551370C (zh) *	2002-05-21	2009-10-21	Cv医药有限公司	雷诺嗪在制备治疗糖尿病的药物组合物中的应用
KR20060124646A (ko) *	2003-12-18	2006-12-05	씨브이 쎄러퓨틱스, 인코포레이티드	1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물
MX2007005367A (es) *	2004-11-09	2007-06-18	Cv Therapeutics Inc	Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca.
JP2008526879A (ja) *	2005-01-06	2008-07-24	シーブイ・セラピューティクス・インコーポレイテッド	ラノラジンを含有する徐放性薬学的処方物
EP1879583A2 (en) *	2005-05-03	2008-01-23	Mutual Pharmaceutical Company, Inc.	Quinine formulations
CN100522169C (zh) *	2005-07-04	2009-08-05	齐鲁制药有限公司	盐酸雷诺嗪缓释制剂及其制备方法
JP2010514696A (ja) *	2006-12-21	2010-05-06	ギリアード・パロ・アルト・インコーポレイテッド	心血管症状の低減
CA2678515A1 (en)	2007-02-13	2008-08-21	Cv Therapeutics, Inc.	Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (ja) *	2007-02-13	2010-05-27	ギリアード・パロ・アルト・インコーポレイテッド	冠微小血管疾患の処置のためのラノラジンの使用
US20090111826A1 (en) *	2007-02-13	2009-04-30	Louis Lange	Use of ranolazine for the treatment of cardiovascular diseases
CA2678325A1 (en) *	2007-02-13	2008-08-21	Cv Therapeutics, Inc.	Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008116083A1 (en) *	2007-03-22	2008-09-25	Cv Therapeutics, Inc.	Use of ranolazine for elevated brain-type natriuretic peptide
CN101896181A (zh) *	2007-05-31	2010-11-24	吉利德帕洛阿尔托股份有限公司	用于升高的脑钠肽的雷诺嗪
KR20110013348A (ko) *	2008-02-06	2011-02-09	길리애드 사이언시즈, 인코포레이티드	통증 치료를 위한 라놀라진의 용도
CA2735653A1 (en) *	2008-09-04	2010-03-11	Gilead Sciences, Inc.	Method of treating atrial fibrillation
WO2010074807A1 (en)	2008-10-30	2010-07-01	Gilead Palo Alto, Inc.	3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
CA2761771A1 (en) *	2009-05-14	2010-11-18	Gilead Sciences, Inc.	Ranolazine for the treatment of cns disorders
US9303038B2 (en)	2011-09-06	2016-04-05	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167990A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of depression
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201407300VA (en)	2012-05-07	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of neurological disorders
US9522884B2 (en)	2012-05-08	2016-12-20	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic disorders
WO2013167993A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en)	2012-05-08	2016-02-23	Cellix Bio Private Limited	Compositions and methods for the treatment of parkinson's disease
US9309233B2 (en)	2012-05-08	2016-04-12	Cellix Bio Private Limited	Compositions and methods for the treatment of blood clotting disorders
US9403826B2 (en)	2012-05-08	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory disorders
WO2013168014A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of familial amyloid polyneuropathy
US9403857B2 (en)	2012-05-10	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en)	2012-05-10	2016-01-26	Cellix Bio Private Limited	Compositions and methods for the treatment of respiratory disorders
WO2013168001A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2013167999A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurologic diseases
US9273061B2 (en)	2012-05-10	2016-03-01	Cellix Bio Private Limited	Compositions and methods for the treatment of chronic pain
US9233161B2 (en)	2012-05-10	2016-01-12	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological conditions
US9339484B2 (en)	2012-05-10	2016-05-17	Cellix Bio Private Limited	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9499526B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en)	2012-05-10	2016-05-24	Cellix Bio Private Limited	Compositions and methods for the treatment of fibromyalgia pain
US9573927B2 (en)	2012-05-10	2017-02-21	Cellix Bio Private Limited	Compositions and methods for the treatment of severe pain
WO2013168015A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of asthma and allergy
WO2013167997A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
WO2013175376A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of local pain
SG11201407326XA (en)	2012-05-23	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for treatment of mucositis
US9434729B2 (en)	2012-05-23	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
NZ701832A (en)	2012-05-23	2016-08-26	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammatory bowel disease
WO2013175347A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
JP2015518854A (ja)	2012-05-23	2015-07-06	セリックスビオプライヴェートリミテッド	多発性硬化症の治療のための組成物および方法
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en)	2012-08-03	2015-11-17	Cellix Bio Private Limited	N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US20150148352A1 (en) *	2012-08-14	2015-05-28	Cellixbio Private Limited	Compositions and methods for the treatment angina and cardiovascular conditions
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
AU2013311349A1 (en)	2012-09-08	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
AU2014276346A1 (en)	2013-06-04	2015-12-24	Cellixbio Private Limited	Compositions and methods for the treatment of diabetes and pre-diabetes
HK1219893A1 (zh)	2013-08-01	2017-04-21	吉利德科学公司	治療長qt綜合征的化合物和方法
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
SG11201706952VA (en)	2014-09-26	2017-10-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of epilepsy and neurological disorders
EP3201168B1 (en)	2014-09-29	2020-03-18	Cellix Bio Private Limited	Compounds and compositions for the treatment of multiple sclerosis
AU2014414316B2 (en)	2014-10-27	2020-04-09	Cellix Bio Private Limited	Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
WO2016088132A1 (en)	2014-12-01	2016-06-09	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja)	2015-01-06	2020-04-22	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	炎症及び疼痛の治療のための組成物及び方法
KR101617683B1 (ko)	2015-01-09	2016-05-03	연세대학교 산학협력단	부정맥 치료제 효과 평가 시스템 및 방법
TW201717919A (zh)	2015-07-02	2017-06-01	國際藥品股份公司	雷諾多重壓縮錠劑
WO2018001582A1 (en)	2016-06-30	2018-01-04	Interquim, S.A.	Ranolazine multiple compressed tablets
CN116808039A (zh) *	2023-03-27	2023-09-29	河南中医药大学第一附属医院	青藤碱在制备钾离子、钠离子通道抑制剂中的应用
WO2025010429A1 (en) *	2023-07-06	2025-01-09	The General Hospital Corporation	Method and apparatus for evaluating cardiac function

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3845770A (en) *	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US4326525A (en) *	1980-10-14	1982-04-27	Alza Corporation	Osmotic device that improves delivery properties of agent in situ
US4567264A (en) *	1983-05-18	1986-01-28	Syntex (U.S.A.) Inc.	Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
US5364620A (en) *	1983-12-22	1994-11-15	Elan Corporation, Plc	Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) *	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4992445A (en) *	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US4902514A (en) *	1988-07-21	1990-02-20	Alza Corporation	Dosage form for administering nilvadipine for treating cardiovascular symptoms
DK0407780T3 (da) *	1989-06-23	1996-09-30	Syntex Inc	Ranolazin og beslægtede piperaziner til anvendelse i behandling af væv, der har været udsat for fysisk eller kemisk skade
JPH03141258A (ja) *	1989-10-25	1991-06-17	Kowa Co	新規なピペラジン誘導体
CA2172513C (en) *	1993-09-24	2008-01-08	Bernard A. Macleod	Aminocyclohexylesters and uses thereof
US6303607B1 (en) *	1998-09-10	2001-10-16	Cv Therapeutics, Inc.	Method for administering a sustained release ranolanolazine formulation
EP1259230A2 (en) *	2000-02-18	2002-11-27	Cv Therapeutics, Inc.	Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US6677336B2 (en) *	2000-02-22	2004-01-13	Cv Therapeutics, Inc.	Substituted piperazine compounds
CN103356996A (zh) *	2000-05-19	2013-10-23	埃米林药品公司	Glp-1用于制备治疗急性冠脉综合征的药物的用途
US20020052377A1 (en) *	2000-07-21	2002-05-02	Wolff Andrew A.	Method for treating angina
US6573264B1 (en) *	2000-10-23	2003-06-03	Cv Therapeutics, Inc.	Heteroaryl alkyl piperazine derivatives
US20080109040A1 (en) *	2002-04-04	2008-05-08	Luiz Belardinelli	Method of treating arrhythmias
US20030220344A1 (en) *	2002-04-04	2003-11-27	Luiz Belardinelli	Method of treating arrhythmias

2003
- 2003-04-03 US US10/406,894 patent/US20030220344A1/en not_active Abandoned
- 2003-04-04 PT PT03723907T patent/PT1490066E/pt unknown
- 2003-04-04 AT AT03723907T patent/ATE397932T1/de active
- 2003-04-04 MX MXPA04009637A patent/MXPA04009637A/es active IP Right Grant
- 2003-04-04 KR KR10-2004-7015749A patent/KR20040099395A/ko not_active Ceased
- 2003-04-04 NZ NZ535610A patent/NZ535610A/en not_active IP Right Cessation
- 2003-04-04 ES ES03723907T patent/ES2304507T3/es not_active Expired - Lifetime
- 2003-04-04 EP EP03723907A patent/EP1490066B1/en not_active Expired - Lifetime
- 2003-04-04 PT PT08004276T patent/PT1930007E/pt unknown
- 2003-04-04 SI SI200331842T patent/SI1930007T1/sl unknown
- 2003-04-04 DK DK08004276.5T patent/DK1930007T3/da active
- 2003-04-04 KR KR1020107021063A patent/KR20100119804A/ko not_active Abandoned
- 2003-04-04 WO PCT/US2003/010434 patent/WO2003086401A1/en not_active Ceased
- 2003-04-04 CN CN200910171650A patent/CN101843619A/zh active Pending
- 2003-04-04 EP EP10002699A patent/EP2198866A1/en not_active Withdrawn
- 2003-04-04 CN CNB038078716A patent/CN100548300C/zh not_active Expired - Fee Related
- 2003-04-04 ES ES08004276T patent/ES2345573T3/es not_active Expired - Lifetime
- 2003-04-04 SI SI200331293T patent/SI1490066T1/sl unknown
- 2003-04-04 DE DE60332975T patent/DE60332975D1/de not_active Expired - Lifetime
- 2003-04-04 CA CA2481192A patent/CA2481192C/en not_active Expired - Fee Related
- 2003-04-04 AU AU2003230810A patent/AU2003230810B2/en not_active Ceased
- 2003-04-04 DK DK03723907T patent/DK1490066T3/da active
- 2003-04-04 DE DE60321550T patent/DE60321550D1/de not_active Expired - Lifetime
- 2003-04-04 JP JP2003583420A patent/JP4608217B2/ja not_active Expired - Fee Related
- 2003-04-04 AT AT08004276T patent/ATE470445T1/de active
- 2003-04-04 EP EP08004276A patent/EP1930007B1/en not_active Expired - Lifetime
2004
- 2004-11-03 NO NO20044783A patent/NO330953B1/no not_active IP Right Cessation
2008
- 2008-09-03 CY CY20081100948T patent/CY1110400T1/el unknown
2009
- 2009-03-05 IL IL197406A patent/IL197406A0/en unknown
- 2009-03-17 AU AU2009201065A patent/AU2009201065B2/en not_active Ceased
- 2009-09-09 US US12/556,417 patent/US20100004255A1/en not_active Abandoned
2011
- 2011-05-09 AU AU2011202135A patent/AU2011202135A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2009201065A1 (en)	2009-04-09
PT1930007E (pt)	2010-08-17
DE60321550D1 (de)	2008-07-24
DE60332975D1 (de)	2010-07-22
CN101843619A (zh)	2010-09-29
ES2345573T3 (es)	2010-09-27
DK1490066T3 (da)	2008-10-13
EP1490066B1 (en)	2008-06-11
US20030220344A1 (en)	2003-11-27
JP2005528393A (ja)	2005-09-22
ES2304507T3 (es)	2008-10-16
KR20100119804A (ko)	2010-11-10
SI1490066T1 (sl)	2008-10-31
HK1120390A1 (en)	2009-04-03
IL197406A0 (en)	2011-07-31
AU2003230810B2 (en)	2009-02-26
AU2003230810A1 (en)	2003-10-27
ATE397932T1 (de)	2008-07-15
JP4608217B2 (ja)	2011-01-12
PT1490066E (pt)	2008-07-22
EP2198866A1 (en)	2010-06-23
CN1646127A (zh)	2005-07-27
EP1930007A1 (en)	2008-06-11
ATE470445T1 (de)	2010-06-15
AU2011202135A1 (en)	2011-05-26
EP1490066A1 (en)	2004-12-29
NO20044783L (no)	2004-11-03
CA2481192C (en)	2012-07-03
CA2481192A1 (en)	2003-10-23
AU2009201065B2 (en)	2011-07-21
NZ535610A (en)	2006-05-26
NO330953B1 (no)	2011-08-22
KR20040099395A (ko)	2004-11-26
CY1110400T1 (el)	2015-04-29
WO2003086401A1 (en)	2003-10-23
EP1930007B1 (en)	2010-06-09
CN100548300C (zh)	2009-10-14
SI1930007T1 (sl)	2010-08-31
MXPA04009637A (es)	2005-07-14
US20100004255A1 (en)	2010-01-07

Publication	Publication Date	Title
DK1490066T3 (da)	2008-10-13	Anvendelse af ranolazin til fremstilling af et medikament til behandling af arytmier
ATE517658T1 (de)	2011-08-15	Arrythmie-klassifizierung und therapiewahl
AU2003284010A1 (en)	2004-05-04	Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
WO2006127238A3 (en)	2007-12-21	Apparatus and methods for performing ablation
WO2004006853A3 (en)	2004-07-08	Treatment and prophylaxis with 4-1bb-binding agents
WO2004062479A3 (en)	2004-11-11	Non-invasive heart treatment device
GB0223038D0 (en)	2002-11-13	Therapeutic compounds
WO2006020060A3 (en)	2007-02-15	Iap binding compounds
WO2007076161A3 (en)	2007-11-08	Compounds with therapeutic activity
NO20011283D0 (no)	2001-03-14	Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon
UA96914C2 (ru)	2011-12-26	Производные 1,4-бензотиазепина, их применение при сердечной недостаточности, фармацевтическая композиция, которая их содержит, и способ лечения
NO330888B1 (no)	2011-08-08	Benzensylfonamidderivater, fremgangsmate for fremstilling av slike, terapeutisk preparatinneholdende slike samt anvendelse av slike for fremstilling av preparat for behandling av sykdom
NO20033434L (no)	2003-09-23	3,7-diazabicyklo(3.3.0)oktaner og anvendelse derav ved behandling av hjertearrytmier
ZA200603593B (en)	2010-10-27	Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
DE60224650D1 (de)	2008-03-06	Vorrichtung zur behandlung von vorhof-fibrillation
DE60206289D1 (de)	2006-02-02	Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
WO2005094554A3 (en)	2007-04-26	Therapeutic agents, methods, and treatments
FI20011298L (fi)	2003-02-10	Puunkäsittelyliuos ja menetelmä puun säilyvyyden parantamiseksi
DE60214207D1 (de)	2006-10-05	Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
MXPA05004121A (es)	2006-02-17	Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
ATE288498T1 (de)	2005-02-15	Methoden zur inhibierung von helicobacter pylori
ATE553763T1 (de)	2012-05-15	Selektive a2a-rezeptorantagonisten zur behandlung von vorhofflimmern
EE200300495A (et)	2003-12-15	3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
WO2002062205A3 (en)	2003-09-12	Methods for diagnosing and treating heart disease
ZA200609220B (en)	2009-02-25	Method of treating dry eye disorders and uveitis